Indian Pharma Firms Launch Generic Semaglutide for Diabetes Treatment
Three Indian pharma firms launched cheaper generic semaglutide injections after the patent expiry, targeting Type 2 diabetes and obesity.
Three Indian pharmaceutical companies have introduced generic semaglutide injections following the patent expiry, offering more affordable treatment options for patients with Type 2 diabetes and obesity.
The companies — Sun Pharma, Zydus Lifesciences, and Dr. Reddy's Laboratories — rolled out their versions a day after Natco Pharma launched its generic semaglutide injection in India, priced at Rs 1,290 per month.
Sun Pharma introduced semaglutide under the brand names Noveltreat and Sematrinity. Noveltreat is indicated for chronic weight management and is available in five dose strengths, while Sematrinity targets Type 2 diabetes that is not adequately controlled and comes in two dose strengths.
The weekly treatment cost for Noveltreat ranges from approximately Rs 900 to Rs 2,000, while Sematrinity is priced between Rs 750 and Rs 1,300, according to reports.
Zydus Lifesciences launched its semaglutide injection in a reusable multi-dose pen device. The drug is marketed as SEMAGLYN, MASHEMA, and ALTERME for both Type 2 diabetes and obesity, with an estimated monthly treatment cost of around Rs 2,200.
Dr. Reddy’s Laboratories announced Obeda, describing it as India’s first DCGI-approved generic semaglutide for Type 2 diabetes. The drug is available in 2 mg and 4 mg pre-filled disposable pens for once-weekly use, priced at Rs 4,200 per month for both strengths.
Semaglutide belongs to the GLP-1 receptor agonist class and has a globally established track record in improving glycaemic control and aiding weight management.
India’s pharmaceutical exports grew by 9.4 per cent in 2024–25 to reach $30.47 billion, and the industry is now aiming for double-digit growth in 2026–27 with strong government backing, according to the Ministry of Commerce and Industry.
The pharmaceutical sector, currently valued at about $60 billion, is projected to expand to $130 billion by 2030, the ministry said.
India ranks third globally in terms of medicine production volume and exports pharmaceutical products to more than 200 countries.
With Inputs From IANS
Dr Bhumika Maikhuri is a Consultant Orthodontist at Sanjeevan Hospital, Delhi. She is also working as a Correspondent and a Medical Writer at Medical Dialogues. She completed her BDS from Dr D Y patil dental college and MDS from Kalinga institute of dental sciences. Apart from dentistry, she has a strong research and scientific writing acumen. At Medical Dialogues, She focusses on medical news, dental news, dental FAQ and medical writing etc.